JPWO2019236496A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019236496A5 JPWO2019236496A5 JP2020567199A JP2020567199A JPWO2019236496A5 JP WO2019236496 A5 JPWO2019236496 A5 JP WO2019236496A5 JP 2020567199 A JP2020567199 A JP 2020567199A JP 2020567199 A JP2020567199 A JP 2020567199A JP WO2019236496 A5 JPWO2019236496 A5 JP WO2019236496A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition
- compound
- pharmaceutically acceptable
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 239000008194 pharmaceutical composition Substances 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 32
- 230000000241 respiratory effect Effects 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 208000009129 Ear Neoplasms Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 4
- 206010043515 Throat cancer Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 230000001079 digestive effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000031083 ear cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000022924 malignant ear neoplasm Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 31
- -1 use Substances 0.000 claims 5
- 238000000034 method Methods 0.000 description 15
- 208000023504 respiratory system disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680324P | 2018-06-04 | 2018-06-04 | |
| US62/680,324 | 2018-06-04 | ||
| PCT/US2019/035247 WO2019236496A1 (en) | 2018-06-04 | 2019-06-03 | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525771A JP2021525771A (ja) | 2021-09-27 |
| JP2021525771A5 JP2021525771A5 (https=) | 2022-06-06 |
| JPWO2019236496A5 true JPWO2019236496A5 (https=) | 2022-06-06 |
| JP7351859B2 JP7351859B2 (ja) | 2023-09-27 |
Family
ID=66913097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567199A Active JP7351859B2 (ja) | 2018-06-04 | 2019-06-03 | Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10857153B2 (https=) |
| EP (1) | EP3802519A1 (https=) |
| JP (1) | JP7351859B2 (https=) |
| CN (1) | CN112513031A (https=) |
| AR (1) | AR114910A1 (https=) |
| TW (1) | TW202003475A (https=) |
| WO (1) | WO2019236496A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| JP7351859B2 (ja) | 2018-06-04 | 2023-09-27 | アプロス セラピューティクス， インコーポレイテッド | Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| ATE283855T1 (de) | 1996-07-03 | 2004-12-15 | Sumitomo Pharma | Neue purinderivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| SI1255752T1 (sl) | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| CN102482233A (zh) | 2009-05-21 | 2012-05-30 | 阿斯利康(瑞典)有限公司 | 新颖的嘧啶衍生物和它们在治疗癌症和其它疾病中的用途 |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2458355T3 (es) * | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| TWI619704B (zh) | 2012-05-18 | 2018-04-01 | 大日本住友製藥股份有限公司 | 羧酸化合物 |
| WO2014128189A1 (en) | 2013-02-21 | 2014-08-28 | Janssen R&D Ireland | 2-aminopyrimidine derivatives for the treatment of viral infections |
| KR102495436B1 (ko) | 2016-12-05 | 2023-02-02 | 에이프로스 테라퓨틱스, 인크. | 산성 기를 함유하는 피리미딘 화합물 |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| JP7351859B2 (ja) | 2018-06-04 | 2023-09-27 | アプロス セラピューティクス， インコーポレイテッド | Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物 |
-
2019
- 2019-06-03 JP JP2020567199A patent/JP7351859B2/ja active Active
- 2019-06-03 EP EP19731568.2A patent/EP3802519A1/en not_active Withdrawn
- 2019-06-03 AR ARP190101499A patent/AR114910A1/es unknown
- 2019-06-03 TW TW108119118A patent/TW202003475A/zh unknown
- 2019-06-03 US US16/429,104 patent/US10857153B2/en not_active Expired - Fee Related
- 2019-06-03 WO PCT/US2019/035247 patent/WO2019236496A1/en not_active Ceased
- 2019-06-03 CN CN201980050020.0A patent/CN112513031A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA004657B1 (ru) | Фармацевтическая композиция на основе обладающих антихолинергическим действием соединений , способ ее получения и применение | |
| JP2004500429A (ja) | チオトロピウム及びロフレポニドを含む医薬用の組み合わせ | |
| WO2001078745A1 (en) | Medical combinations comprising formoterol and fluticasone proprionate | |
| JP2004500430A (ja) | ホルモテロール及びブデソニドを含有する医薬用の組み合わせ | |
| EP3578169A1 (en) | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol | |
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| JP2005508963A (ja) | 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ | |
| RU2015129076A (ru) | Арилалкил- и арилоксиалкил-замещенные соединения, блокирующие эпителиальный натриевый канал | |
| TW201031408A (en) | Novel methods | |
| JP2021525771A5 (https=) | ||
| JP2019505596A5 (https=) | ||
| JP2004513099A (ja) | 喘息を治療するためのトルテロジンの使用 | |
| US6946486B2 (en) | Quaternary ammonium compounds | |
| JPWO2019236496A5 (https=) | ||
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2004500434A (ja) | サルメテロールとブデソニドを含む組合せ医薬 | |
| US6951950B2 (en) | Quaternary ammonium compounds | |
| WO2001078744A1 (en) | Medical combinations comprising formoterol and mometasone | |
| US20150313841A1 (en) | Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases | |
| JP2004500431A (ja) | （ｒ，ｒ）−ホルモテロール及びロフレポニドを含む医薬組成物 | |
| WO2020031148A1 (en) | Pharmaceutical composition, medicinal product and method of treatment of bronchopulmonary obstructive diseases | |
| US6878730B2 (en) | Quaternary ammonium compounds | |
| US20040138253A1 (en) | Quaternary ammonium compounds | |
| JP2009506029A5 (https=) | ||
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 |